Please login to the form below

Not currently logged in
Email:
Password:

Biogen/ Vernalis call halt to Parkinson's drug

Biogen and Vernalis are discontinuing development of the drug vipadenant for Parkinson's disease, due to "findings in preclinical toxicology studies"

Biogen and Vernalis are discontinuing development of the drug vipadenant for Parkinson's disease, although it achieved positive results in phase II studies, due to "findings in preclinical toxicology studies". However, work on a next-generation compound is likely to go into phase 1 studies in early 2011.

Biogen will continue to fund all development costs under the collaboration and Vernalis said it can earn milestones and royalties on the successful development of the next-generation compound, "to the extent that milestones have not already been paid for vipadenant".

Vipadenant is an adenosine A2A receptor antagonist. Experts believe that A2A receptor antagonists could have advantages over conventional dopaminegic strategies. They may be able to help restore motor function in patients with Parkinson's disease, without the side effects, such as nausea and dyskinesia (uncontrolled movement), associated with current treatments.

Vipadenant is one of a small number of adenosine A2A receptor antagonists currently in development by major pharmaceutical companies and their partners.

From their London headquarters, Vernalis's chief executive, Ian Garland said that they were "of course, disappointed" about vipadenant, but hopes are still high for its novel A2A receptor antagonist programme with a next-generation Vernalis compound.

19th July 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
Employee wellbeing in creative agencies: three tips to get you started
Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
Managing unhelpful pressure in your creative agency: the human approach
Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...